News & Updates

Our Purpose:
To be a driving force in the early detection of lung cancer.

January 4, 2022

LungLife AI, Inc. - CPT® Code granted by American Medical Association

4 January 2022 LungLife AI, Inc. (the “Company” or “LungLife”)   CPT® Code granted by American Medical Association Successful grant marks first step facilitating commercial reimbursement   LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT® Proprietary Laboratory Analyses (PLA) code for its LungLB® […]
• Read More
November 22, 2021

LungLife AI Clinical Laboratory achieves CAP accreditation

19 November 2021 LungLife AI, Inc. (the “Company” or “LungLife”)   LungLife AI Clinical Laboratory achieves CAP accreditation Independent inspection confirms highest standard of care for laboratory patients   LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its clinical laboratory in Thousand Oaks, California […]
• Read More
November 22, 2021

LungLife AI - Block Listing Application

10 November 2021 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Application   LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the “Block Admission”) has been made to the London Stock Exchange for up to 1,356,139 common shares of US […]
• Read More
October 12, 2021

LungLife AI - PLA Code application submitted in first step in reimbursement process

12 October 2021   LungLife AI, Inc. (the “Company” or “LungLife”)  PLA Code application submitted in first step in reimbursement process LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical […]
• Read More
September 9, 2021

LungLife AI - Half-year Report

9 September 2021 LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer enhanced by artificial intelligence, announces its maiden unaudited half-year report for the six months ended 30 June 2021 following admission to trading on AIM on 8 […]
• Read More
September 3, 2021

LungLife AI - Notice of Results & Investor Presentation

3 September 2021 LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its maiden unaudited half-year report for the six months ended 30 June 2021 will be announced on Thursday 9 September 2021. […]
• Read More
July 12, 2021

TR-1 Lunglife AI Inc (12.07.21)

TR-1 Lunglife AI Inc (12.07.21) [PDF]
• Read More
July 9, 2021

TR-1 Lunglife AI Inc (09.07.21)

TR-1 Lunglife AI Inc (09.07.21) [PDF]
• Read More
July 8, 2021

TR1-Notification of Major Interest in LungLife AI Inc - (08.07.2021) 

TR1-Notification of Major Interest in LungLife AI Inc - (08.07.2021) [PDF]
• Read More

Investor inquiries

© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
magnifiercrossmenuchevron-down